CLAIMS

1. A pharmaceutical composition comprising a ROBO2 inhibitor that inhibits ROBO2 biological activity, in which the ROBO2 inhibitor is a soluble ROBO2 protein comprising a fusion polypeptide comprising both the Ig1 and Ig2 SLIT binding domains of ROBO2 with no intracellular ROBO2 domain.

2. A pharmaceutical composition according to Claim 1, in which the ROBO2 inhibitor prevents or reduces the binding of the ROBO2 polypeptide to SLIT2, to Nck, or to both.

3. A pharmaceutical composition according to Claim 1 or 2, in which the Ig1 SLIT binding domain comprises amino acid residues 46-145 of SEQ ID NO: 1 or amino acid residues 30-129 of SEQ ID NO: 3.

4. A pharmaceutical composition according to Claim 1, 2 or 3, in which the Ig2 SLIT binding domain comprises amino acid residues 151-237 of SEQ ID NO: 1 or amino acid residues 135-221 of SEQ ID NO: 3.

5. A pharmaceutical composition according to any preceding claim, in which the soluble ROBO2 protein comprises amino acid residues 30-129 and amino acid residues 135-221 of SEQ ID NO: 3.

6. A pharmaceutical composition according to any preceding claim for use in treating a subject having or at risk for a chronic kidney disease or proteinuria.

7. A pharmaceutical composition according to Claim 6, in which the chronic kidney disease or proteinuria is caused by diabetic nephropathy or high blood pressure.